Dipeptide Diaminobutyroyl Benzylamide Diacetate
Also known as: Waglerin-1 mimetic, Tripeptide-3
Dipeptide Diaminobutyroyl Benzylamide Diacetate (also called Waglerin-1 mimetic or Tripeptide-3) is a cosmetic nicotinic antagonist mimetic. This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction.
For research use only.
Key Facts
- CAS
- 823202-99-9
- Molecular Weight (MW)
- —
- Half-life
- Topical; systemic PK not established
- FDA status
- Not Approved
- Administration Route
- Topical
- Frequency
- —
- Last updated
- Sep 26, 2026
- Reviewed
- Aug 30, 2026
- Targets
- Muscle nAChR (model systems)
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Dec 2025, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg
- $1.05/mg
Research summary
Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug.
Peptide Library's Dipeptide Diaminobutyroyl Benzylamide Diacetate profile summarises 4 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- Per cosmetic formulation
- Frequency
- —
- Cycle
- —
- Administration Route
- Topical
- Reconstitution Guide
- —
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Dipeptide Diaminobutyroyl Benzylamide Diacetate is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C23H37N5O7 (salt forms vary) |
|---|---|
| Molecular weight | — |
| CAS number | 823202-99-9 |
| Half-life | Topical; systemic PK not established |
| Appearance | Clear solution or powder (cosmetic grade) |
| Formulation | Topical Cream |
| PubChem CID | 71465152 |
| FDA UNII | 38H206R00R |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction. Applied topically the intent is to reduce the microcontractions of facial expression muscles that produce dynamic lines, giving a mechanism conceptually parallel to botulinum toxin but acting on the receptor rather than on vesicle fusion, and far weaker. Whether a topically applied dipeptide reaches the neuromuscular junction in meaningful concentration is the central unresolved question; evidence is largely supplier-derived.
Origin
Synthetic tripeptide analog of temple-viper waglerin-1.
Targets
Studies
- Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests
- Microemulsions and Nanoemulsions for Topical Delivery of Tripeptide-3: From Design of Experiment to Anti-Sebum Efficacy on Facial Skin
- Role of Peptides in Skeletal Muscle Wasting: A Scoping Review
- Antidiabetic Potential of a Trimeric Anthranilic Acid Peptide Isolated from Malbranchea flocciformis
Regulatory & research status
Dipeptide Diaminobutyroyl Benzylamide Diacetate is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.
| FDA status | Not Approved |
|---|---|
| Availability | OTC / Supplement |
| WADA (sport) | Permitted |
| Library classification | Research-Only |
Benefits
Dipeptide Diaminobutyroyl Benzylamide Diacetate side effects
Side Effects
- Irritation
- Redness
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Cosmetic peptides in this library are formulated into topical products; follow the product label rather than the reconstitution guidance above.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Dipeptide Diaminobutyroyl Benzylamide Diacetate: frequently asked questions
What is Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Waglerin-1–inspired tripeptide used in cosmetics to reduce expression-line appearance. Topical cosmetic active, not an FDA drug.
How does Dipeptide Diaminobutyroyl Benzylamide Diacetate work?
This dipeptide is a synthetic mimetic of waglerin-1, a component of temple viper venom that antagonises the muscle-type nicotinic acetylcholine receptor. In vitro it shows reversible antagonist-like activity at the postsynaptic receptor of the neuromuscular junction, reducing the depolarisation that initiates muscle contraction.
Is Dipeptide Diaminobutyroyl Benzylamide Diacetate FDA approved?
No. Dipeptide Diaminobutyroyl Benzylamide Diacetate is not approved by the FDA for any indication and is categorised as otc / supplement. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.
What is the half-life of Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Reported half-life for Dipeptide Diaminobutyroyl Benzylamide Diacetate is Topical; systemic PK not established. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Dipeptide Diaminobutyroyl Benzylamide Diacetate banned in sport?
Dipeptide Diaminobutyroyl Benzylamide Diacetate is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Dipeptide Diaminobutyroyl Benzylamide Diacetate?
Compounds most often compared with Dipeptide Diaminobutyroyl Benzylamide Diacetate include Acetyl Hexapeptide-8, Acetyl Octapeptide-3, Acetyl Tetrapeptide-3 and AHK-Cu. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- PubChem SYN-AKEExternal reference
- Anti-aging activity of Syn-Ake peptide by in silico approaches and in vitro tests — J Biomol Struct Dyn, 2024External reference
- Microemulsions and Nanoemulsions for Topical Delivery of Tripeptide-3: From Design of Experiment to Anti-Sebum Efficacy on Facial Skin — Pharmaceutics, 2024External reference
- Role of Peptides in Skeletal Muscle Wasting: A Scoping Review — J Cachexia Sarcopenia Muscle, 2025External reference
- Antidiabetic Potential of a Trimeric Anthranilic Acid Peptide Isolated from Malbranchea flocciformis — Chem Biodivers, 2024External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Sep 26, 2026 · Version 3
This Dipeptide Diaminobutyroyl Benzylamide Diacetate profile is compiled from published literature (4 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Dipeptide Diaminobutyroyl Benzylamide Diacetate research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →